RU2009117653A - USE OF SUBSTITUTED PYRAZINONE DERIVATIVES AS A MEDICINAL PRODUCT - Google Patents
USE OF SUBSTITUTED PYRAZINONE DERIVATIVES AS A MEDICINAL PRODUCT Download PDFInfo
- Publication number
- RU2009117653A RU2009117653A RU2009117653/04A RU2009117653A RU2009117653A RU 2009117653 A RU2009117653 A RU 2009117653A RU 2009117653/04 A RU2009117653/04 A RU 2009117653/04A RU 2009117653 A RU2009117653 A RU 2009117653A RU 2009117653 A RU2009117653 A RU 2009117653A
- Authority
- RU
- Russia
- Prior art keywords
- radical
- group
- alkyl
- het
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim 1, having selective 2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.
Claims (25)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06122173.5 | 2006-10-12 | ||
EP06122173 | 2006-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2009117653A true RU2009117653A (en) | 2010-11-20 |
Family
ID=37781925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009117653/04A RU2009117653A (en) | 2006-10-12 | 2007-10-10 | USE OF SUBSTITUTED PYRAZINONE DERIVATIVES AS A MEDICINAL PRODUCT |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100105694A1 (en) |
EP (1) | EP2091942B1 (en) |
JP (1) | JP2010505908A (en) |
CN (1) | CN101522660A (en) |
AT (1) | ATE457985T1 (en) |
AU (1) | AU2007306382A1 (en) |
CA (1) | CA2659923A1 (en) |
DE (1) | DE602007004881D1 (en) |
DK (1) | DK2091942T3 (en) |
ES (1) | ES2339998T3 (en) |
IL (1) | IL198072A0 (en) |
MX (1) | MX2009003849A (en) |
RU (1) | RU2009117653A (en) |
WO (1) | WO2008043775A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102008015032A1 (en) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituted pyrazolamides and their use |
DE102008015033A1 (en) | 2008-03-17 | 2009-09-24 | Aicuris Gmbh & Co. Kg | Substituted (pyrazolyl-carbonyl) imidazolidinones and their use |
DE102008062863A1 (en) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituted (thiophenyl-carbonyl) imidazolidinones and their use |
DE102008062878A1 (en) | 2008-12-17 | 2010-06-24 | Aicuris Gmbh & Co. Kg | Substituted furancarboxamides and their use |
FR2976287B1 (en) | 2011-06-09 | 2013-07-05 | Pf Medicament | BENZOQUINOLIZIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS |
JP2016523918A (en) * | 2013-06-27 | 2016-08-12 | シーダーズ−サイナイ メディカル センター | Adrenergic receptor antagonists for the prevention and treatment of neurodegenerative conditions |
CN108178759B (en) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | Synthesis method of α -adrenoceptor antagonist |
WO2022065354A1 (en) * | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | Alpha-2 adrenergic receptor antagonist |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ537629A (en) * | 2002-07-19 | 2007-05-31 | Biovitrum Ab | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders |
-
2007
- 2007-10-10 JP JP2009531832A patent/JP2010505908A/en not_active Withdrawn
- 2007-10-10 ES ES07821116T patent/ES2339998T3/en active Active
- 2007-10-10 DE DE602007004881T patent/DE602007004881D1/en active Active
- 2007-10-10 EP EP07821116A patent/EP2091942B1/en active Active
- 2007-10-10 US US12/445,243 patent/US20100105694A1/en not_active Abandoned
- 2007-10-10 AU AU2007306382A patent/AU2007306382A1/en not_active Abandoned
- 2007-10-10 WO PCT/EP2007/060748 patent/WO2008043775A1/en active Application Filing
- 2007-10-10 RU RU2009117653/04A patent/RU2009117653A/en not_active Application Discontinuation
- 2007-10-10 AT AT07821116T patent/ATE457985T1/en active
- 2007-10-10 DK DK07821116.6T patent/DK2091942T3/en active
- 2007-10-10 CN CNA2007800380865A patent/CN101522660A/en active Pending
- 2007-10-10 MX MX2009003849A patent/MX2009003849A/en unknown
- 2007-10-10 CA CA002659923A patent/CA2659923A1/en not_active Abandoned
-
2009
- 2009-04-07 IL IL198072A patent/IL198072A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009003849A (en) | 2009-04-23 |
CA2659923A1 (en) | 2008-04-17 |
US20100105694A1 (en) | 2010-04-29 |
ATE457985T1 (en) | 2010-03-15 |
CN101522660A (en) | 2009-09-02 |
ES2339998T3 (en) | 2010-05-27 |
JP2010505908A (en) | 2010-02-25 |
DK2091942T3 (en) | 2010-05-17 |
DE602007004881D1 (en) | 2010-04-01 |
AU2007306382A1 (en) | 2008-04-17 |
EP2091942B1 (en) | 2010-02-17 |
EP2091942A1 (en) | 2009-08-26 |
WO2008043775A1 (en) | 2008-04-17 |
IL198072A0 (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11945815B2 (en) | PTPN11 inhibitors | |
RU2009117653A (en) | USE OF SUBSTITUTED PYRAZINONE DERIVATIVES AS A MEDICINAL PRODUCT | |
US20230109858A1 (en) | Heterocyclic inhibitors of ptpn11 | |
JP5997763B2 (en) | Macrocyclic compounds as protein kinase inhibitors | |
AU2005214373B2 (en) | Quinazoline derivatives and therapeutic use thereof | |
KR102598246B1 (en) | Heterocyclic compounds as JAK inhibitors and salts thereof and therapeutic uses | |
JP2019524665A (en) | CXCR4 inhibitors and uses thereof | |
US20240115682A1 (en) | Methods of treating cancer using heteroaryl-biphenyl amide derivatives | |
WO2021060453A1 (en) | Crosslinked optically active secondary amine derivative | |
RU2008150485A (en) | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINAL PRODUCT | |
JP2016514727A (en) | Combination of a catalytic MTORC1 / 2 inhibitor and a selective inhibitor of Aurora A kinase | |
US11530181B2 (en) | IL-6 inhibitors and methods of treatment | |
MX2009006454A (en) | Spiro-piperidine derivatives. | |
JP2014501772A (en) | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and their pharmaceutical use | |
WO2020150115A1 (en) | Nlrp3 modulators | |
MX2009005504A (en) | Spiro-piperidine derivatives as via receptor antagonists. | |
RU2008129656A (en) | SUBSTITUTED PYRAZINONE DERIVATIVES AS AN ALPHA-2C-ADRENORECEPTOR ANTAGONISTS | |
US11466017B2 (en) | Heterocyclic inhibitors of PTPN11 | |
CA3239257A1 (en) | Compounds | |
WO2023099072A1 (en) | Compounds | |
EP4087842A1 (en) | Nlrp3 modulators | |
CA3233567A1 (en) | Combination therapies of kras g12d inhibitors with pan erbb family inhibitors | |
TW202400578A (en) | Novel compound and its use for inhibiting checkpoint kinase 2 | |
TH136297A (en) | Hetero-aromatic phenylimidazole derivatives That is an enzyme PDE10A inhibitor (Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110314 |